Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BEAM
BEAM THERAPEUTICS INC.
NASDAQ
$29.66
▲ UP 0.68% (0.20)

KEY STATISTICS

Market Cap$3.04 B
52w High$38.26
52w Low$19.36
Dividend Yield4.80%
FrequencyQuarterly
P/E-9.02
Volume1.18M
Shares Out.102.88M

COMPANY

LEADERSHIP

John Evans
CHIEF EXECUTIVE
John Evans

COMPENSATION 2026

Salary$755,000
Stock Awards$1,513,575
Incentive Plan Pay$662,513
All Other Comp.$10,684
Total$5,818,525

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 6, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
540

PRICE TARGET

Target High$80.00
Target Low$39.00
Target Median$59.50
Target Consensus$59.50

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$8.72M
NOV
3
TUE

PRICE

$29.66 ▲ UP 0.68% (+$0.20)
$29.20$29.40$29.60$29.809:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM29.66

About Beam Therapeutics Inc.

https://www.beamtx.com ↗

Beam Therapeutics Inc. develops precision genetic medicines for serious diseases, including sickle cell, beta thalassemia, leukemia, and liver disorders, through innovative therapies and collaborations with leading institutions.

INDUSTRY

Biotechnology

A PRODUCT BEAM THERAPEUTICS INC. IS KNOWN FOR

Ristoglogene autogetemcel (risto-cel)
Ristoglogene autogetemcel (risto-cel)

Ristoglogene autogetemcel (formerly BEAM-101) is an investigational autologous stem cell therapy in Phase 1/2 trials, using base editing to increase fetal hemoglobin and potentially provide a one-time treatment for severe sickle cell disease, with...

COMPETITORS

COMPETITOR
CRSP COMPARE
EDIT COMPARE
NTLA COMPARE
PRME COMPARE

Revenue by Products

IconPRODUCTQ2-2011
Home And Security$889.7M
Spirits$702.7M

Revenue by Geography

MapREGIONQ1-2013Q2-2013Q3-2013Q4-2013
North America$364M $410.4M ▲$374.5M ▼$413.6M ▲
EMEA— $116.9M $124.5M ▲$198.9M ▲
Asia Pacific South America$108.1M $110.3M ▲$99.7M ▼$127M ▲
Europe Middle East and Africa$105.6M — — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
171
LISTED HERE
26
RANKED BY POSITION SIZE
ARKK
2.63% · 5.9M
XBI
0.92% · 3.6M
VTS.AX
0.00% · 3.3M
XSU.TO
0.09% · 2.5M
SCHA
0.06% · 471.9K
DFAS
0.06% · 329.1K
FESM
0.14% · 312.7K
FYC
0.46% · 223.2K
AVSC
0.17% · 186.0K
PRFZ
0.14% · 134.6K
LABU
0.61% · 119.8K
TMSL
0.11% · 116.1K
XRS2.F
0.09% · 89.7K
GNOM
2.11% · 66.3K
JSML
0.43% · 53.9K
BBSC
0.11% · 26.5K
WDNA.L
1.68% · 24.2K
BBC
0.63% · 10.8K
HELX
0.77% · 8.1K
MEDX
1.30% · 7.6K
RTWP.L
0.09% · 7.0K
GSSC
0.02% · 6.0K
HLTH
2.28% · 6.0K
TILT
0.01% · 5.5K
URTY
0.04% · 3.9K
RFLR
0.12% · 3.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
85.85%
HOLDERS
369
TOP 12 OF 369 · RANKED BY POSITION SIZE
Fmr LLC
12.6M sh · $432.74M
Ark Investment Management LLC
12.5M sh · $345.59M
Farallon Capital Management LLC
10.2M sh · $351.31M
Vanguard Group Inc
9.3M sh · $224.52M
Blackrock, Inc.
9.0M sh · $308.8M
Blackrock Inc.
7.6M sh · $178.87M
State Street Corp
5.8M sh · $199.99M
Sumitomo Mitsui Trust Holdings, Inc.
4.8M sh · $117.24M
Nikko Asset Management Americas, Inc.
4.8M sh · $117.24M
Arch Venture Management, LLC
4.5M sh · $108.19M
Kynam Capital Management, LP
3.7M sh · $87.75M
Price T Rowe Associates Inc /Md/
3.4M sh · $117.21M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Simon Amy
Sale · 16.7K shares
2026-07-27
★
OFFICER: CHIEF MEDICAL OFFICER
Simon Amy
Sale · 373 shares
2026-06-30
★
DIRECTOR, OFFICER: CEO
Evans John M.
Sale · 11.6K shares
2026-06-29
★
DIRECTOR, OFFICER: CEO
Evans John M.
Sale · 6.3K shares
2026-06-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 2
SECTOR PERFORM 1
OVERWEIGHT 1
7 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY B of A Securities BUY Bernstein OUTPERFORM Citigroup BUY Wedbush OUTPERFORM RBC Capital SECTOR PERFORM JP Morgan OVERWEIGHT

SECTORS PEERS

PEERPRICE
IBRX$8.04COMPARE
COGT$34.79COMPARE
IDYA$39.79COMPARE
RCUS$29.67COMPARE
DNLI$22.34COMPARE
MLYS$27.89COMPARE
AGIO$33.20COMPARE
RXRX$3.68COMPARE